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Background
The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone 
(CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for pa-
tients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient 
response to R-CHOP have not been established. We aimed to evaluate the impact of 
R-CHOP compared with CHOP in patients with DLBCL and to establish clinical predictors 
of better outcomes in these patients.
Methods
We retrospectively identified 177 patients diagnosed with CD20-positive DLBCL and 
treated with CHOP (N=82) or R-CHOP (N=95). The response rate, event-free survival 
(EFS), and overall survival (OS) rates were compared between the 2 treatment groups. 
All patients were classified into primary extranodal lymphoma (PENL) or nodal lymphoma 
(NL) subgroups, and the clinical parameters of each subgroup were analyzed. 
Results
The overall response rate was higher in R-CHOP group (95% vs. 84%, P=0.07). The 3-year 
EFS rate was significantly higher in R-CHOP group (71% vs. 52%, P=0.013), but the OS 
rate was comparable between the 2 groups (79% vs. 69%, P=0.23). A significant survival 
benefit was seen with R-CHOP compared to CHOP therapy in NL patients (P=0.002 for 
EFS and 0.04 for OS). Multivariate analyses confirmed that R-CHOP therapy is an in-
dependent prognostic factor for EFS (hazard ratio of 0.32 [0.17-0.62], P=0.001) and OS 
(hazard ratio of 0.4 [0.18-0.87], P=0.02) in NL patients. 
Conclusion
Patients in the PENL group did not benefit from R-CHOP chemotherapy.
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INTRODUCTION
  Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon subtype of non-Hodgkin’s lymphoma (NHL), account-
ing for approximately 30-40% of lymphoma cases [1, 2]. 
For several decades, the cyclophosphamide, doxorubicin, 
vincristine, and prednisone (CHOP) chemotherapy regimen 
has been considered the gold standard for treatment of DLBCL, 
on the basis of serial clinical investigations in which other 
second- and third-generation chemotherapy regimens failed 
to demonstrate an advantage [3, 4]. The recent introduction 
of rituximab, a chimeric IgG1 monoclonal antibody targeting 
CD20, has led to alterations in treatment strategies for these 
patients. Rituximab, originally investigated for utility in pa-
tients with relapsed and refractory follicular and low-grade 
N H L ,  s h o w e d  p r o m i s i n g  e f f i c a c y  f o r  D L B C L ,  b o t h  a l o n e  
and in combination with CHOP (R-CHOP) chemotherapy, 
in phase II studies [5, 6]. Recent studies comparing the 
R-CHOP and CHOP regimens demonstrated the superiority 
of R-CHOP therapy, which led to significantly higher com-
plete response (CR) rates and survival benefits in both elderly 
and young DLBCL patients. Accordingly, R-CHOP has re-
placed CHOP as a new standard treatment [7-10].Korean J Hematol 2011;46:103-10.
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Although most patients exhibit improved outcomes with 
rituximab, some patients fail to respond to R-CHOP therapy. 
There is currently an urgent need to identify new prognostic 
factors in the R-CHOP era. To date, the International Prog-
nostic Index (IPI) has been used as a powerful clinical tool 
to predict outcomes for patients with aggressive NHL [11]. 
However, the issue of whether the traditional IPI is relevant 
for patients subjected to R-CHOP chemotherapy remains 
to be established. In a recent study on patients treated with 
R-CHOP, IPI could not be effectively used to distinguish 
4 discrete risk groups, although it remained partially pre-
dictive, and a revised IPI to identify 3 risk groups proved 
a better predictor [12]. Other studies have attempted to eval-
uate molecular prognostic markers, such as Bcl-2 and Bcl-6, 
in DLBCL patients treated with R-CHOP [13, 14].
Approximately 25-40% of NHLs arise from tissues other 
than lymph nodes. These lymphomas are often referred to 
as primary extranodal lymphomas (PENLs), although the 
exact definition is not established and currently a subject 
of controversy [15-17]. The incidence of PENL is higher 
in areas of Asia, including Korea, than in Western countries 
[18-20]. Several studies have attempted to elucidate the dif-
ferences between PENL and nodal lymphoma (NL) in terms 
of etiology, clinical behavior, response to treatment, and 
outcome. A number of investigators have identified sig-
nificant molecular differences between extranodal and nodal 
lymphoma, suggesting distinct genetic origins [21-24]. 
However, the clinical and prognostic differences between 
these 2 types of NHL are unclear at present. To date, few 
studies have been carried out to establish a correlation, if 
any, between rituximab treatment and both NHL types.
In this study, we conducted a retrospective analysis to 
evaluate the impact of the R-CHOP regimen and sought 
to identify clinical prognostic factors of DLBCL, particularly 
in PENL and NL patients treated with R-CHOP or CHOP 
alone. 
MATERIALS AND METHODS
1. Patients
Using prospectively designed Asan Medical Center (AMC) 
registry data for NHL, 489 patients newly diagnosed with 
DLBCL from January 2001 to November 2005 were selected 
for this study. All patients with biopsy-proven DLBCL at 
any age, stage, and performance status, and treated with 
CHOP or R-CHOP as first-line chemotherapy, were eligible. 
Patients with primary central nervous system (CNS) lympho-
ma or CD20-negative DLBCL were excluded. In total, we 
identified 177 eligible patients, of whom 82 were treated 
with the CHOP regimen (CHOP group) between January 
2001 and October 2005, and 95 with the R-CHOP regimen 
(R-CHOP group) between June 2003 and November 2005. 
All enrolled patients were subclassified as either PENL or 
NL,  acco rding to  t he main  origin  o f d isease. P ENL  was d efined 
as lymphoma with either no or minor nodal involvement, 
along with a clinically dominant extranodal component after 
routine staging procedures [15].
2. Treatment
The CHOP group received a standard regimen consisting 
of cyclophosphamide (750 mg/m
2 intravenously), doxor-
ubicin (50 mg/m
2 intravenously), and vincristine (1.4 mg/m
2, 
maximum total 2 mg intravenously) for 1 day, and prednisone 
(100 mg orally) was given for 5 days every 3 weeks. In 
R-CHOP group, rituximab was administered at a dose of 
375 mg/m
2 along with the standard CHOP regimen every 
3 weeks. For patients with stage I or II DLBCL, 3 or 4 
cycles of chemotherapy were performed, followed by radio-
therapy with curative intent. For stage III or IV patients, 
5 or 6 cycles of chemotherapy were administered. A number 
of patients received up to 9 cycles of chemotherapy or addi-
tional radiotherapy at the physician’s discretion. Second- 
and third-line chemotherapy or high-dose chemotherapy 
with stem cell rescue were administered to patients who 
displayed relapse of disease or failure to respond to first-line 
chemotherapy.
3. Statistical analysis and definitions
Patient characteristics and therapeutic outcomes were 
compared between CHOP and R-CHOP groups and between 
PENL and NL groups. The basic patient characteristics of 
the 2 groups were compared using Fisher’s exact test. Res-
ponse criteria were defined according to the Revised Res-
ponse Criteria for Malignant Lymphoma [25]. Overall surviv-
al (OS) was defined as the time from the beginning of 
first-line chemotherapy to the date of death as a result of 
any cause. Event-free survival (EFS) was defined as the time 
from the beginning of first-line chemotherapy to appearance 
of any symptom of treatment failure, including disease pro-
gression or discontinuation of treatment for any reason 
(toxicity, patient preference, initiation of new treatment 
without documented progression, or death). The Kaplan- 
Meier method was employed to assess the OS and EFS rates 
of patients in each group. Survival was compared between 
the 2 groups with the 2-sided log-rank test. For the subgroup 
analysis, multivariate analysis was performed using the Cox 
proportional hazards model. We analyzed the data with the 
Statistical Software Package for the Social Sciences (SPSS 
version 12.0 for Windows; SPSS, Chicago, IL, USA).
RESULTS
1. Basic patient characteristics
The median age of all 177 patients, including 96 men 
(54%), was 56 years (range, 15-81). CHOP group consisted 
of 82 patients, while 95 patients were in R-CHOP group. 
The characteristics of the patients from both groups are sum-
marized in Table 1. There was no statistically significant 
difference between the 2 groups in terms of clinical para-
meters. Among the 177 patients, 72 (41%) were in PENL 
group and 105 (59%) were in NL group. Clinical parameters 
were similar between the PENL and NL groups, except for Korean J Hematol 2011;46:103-10.
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Table 2. Comparison of treatment responses of PENL and NL groups according to the treatment regimen.
PENL (N=72) NL (N=105)
CHOP (%)
N=32
R-CHOP (%)
N=40
P
b) CHOP (%)
N=50
R-CHOP (%)
N=55
P
b)
CR
a) 24 (75.0) 27 (67.5) 0.57 29 (58.0) 46 (83.6) 0.01
PR
a)   4 (12.5)   8 (20.0) 12 (24.0)   9 (16.4)
OR
a) 28 (87.5) 35 (87.5) 1.00 41 (82.0) 55 (100) 0.01
a)7 patients were not evaluated (4 in the PENL and 3 in the NL group), 
b)Fisher’s exact test.
Abbreviations: PENL, primary extranodal lymphoma; NL, nodal lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, and pre-
dnisone; R-CHOP, rituximab-CHOP; CR, complete response; PR, partial response; OR, overall response.
Table 1. Baseline patient characteristics in CHOP and R-CHOP 
groups.
Characteristics
CHOP (%)
N=82
R-CHOP (%)
N=95
P
Median age, years (range) 58 (15-79) 56 (16-81) 0.76
　≤60 49 (59.8) 59 (62.1)
　>60 33 (40.2) 36 (37.9)
Sex 0.76
　Male 43 (52.4) 53 (55.8)
　Female 39 (47.6) 42 (44.2)
ECOG PS 0.27
　0-1 78 (95.1) 86 (90.5)
　≥2   4 (4.9)   9 (9.5)
Stage 0.37
　I-II 41 (50.0) 41 (43.2)
　III-IV 41 (50.0) 54 (56.8)
No. of extranodal sites 0.49
　0 35 (42.7) 34 (35.8)
　1 37 (45.1) 44 (46.3)
　＞1 10 (12.2) 17 (17.9)
LDH 0.21
　Normal 27 (34.2) 41 (43.2)
　Elevated 52 (65.8) 52 (54.7)
B symptoms 25 (30.5) 27 (28.4) 0.87
Bulky tumor (≥9 cm)   2 (2.4)   5 (5.3) 0.45
BM involvement   7 (8.5) 15 (15.8) 0.17
IPI 0.36
　Low 38 (46.3) 46 (48.4)
　Low-intermediate 22 (26.8) 17 (17.9)
　High-intermediate 20 (24.4) 26 (27.4)
　High   2 (2.4)   6 (6.3)
PENL vs. NL 0.76
　PENL 32 (39.0) 40 (42.1)
　NL 50 (61.0) 55 (57.9)
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincris-
tine, and prednisone; R-CHOP, rituximab-CHOP; ECOG PS, 
Eastern Clinical Oncology Group performance scale; LDH, lactate 
dehydrogenase; BM, bone marrow; IPI, international prognostic 
index; PENL, primary extranodal lymphoma; NL, nodal lymphoma.
performance status and number of extranodal sites. NL group 
contained more patients with a good performance score (0-1) 
than PENL group (96% vs. 88%, P=0.04). The most common 
primary site of PENL was stomach (18/72 patients, 25%), 
followed by small bowel (14, 20%), head and neck (18%), 
large bowel (8%), and genitourinary tract (6%). 
2. Treatment and responses
Patients in both CHOP and R-CHOP groups received a 
median of 5 cycles (range, 1-9) of first-line chemotherapy. 
The CR rate was higher in R-CHOP than in CHOP group, 
but the difference was not significant (77% vs. 65%, P=0.16). 
The overall response rate (ORR) was also higher in R-CHOP 
group, but not to a significant extent (95% vs. 84%, P=0.07). 
Comparison analyses revealed no differences between the 
PENL and NL groups in CR rates (71% vs. 71%, P=0.86) 
and ORRs (88% vs. 91%, P=0.76). In addition, subgroup 
analysis of the response to each treatment regimen was car-
ried out. In NL group, patients administered R-CHOP regi-
men displayed a significantly higher CR rate (84% vs. 58%, 
P=0.01) and ORR (100% vs. 82%, P=0.008) than those treated 
with CHOP. In contrast, in PENL group, no differences 
were evident in terms of CR rate (68% vs. 75%, P=0.57) 
or ORR (88% vs. 88%, P=1.00) between the R-CHOP and 
CHOP regimens. These results are presented in Table 2. 
Patients who experienced disease recurrence and pro-
gression after first-line CHOP or R-CHOP therapy were 
treated with a variety of salvage regimens, including high- 
dose chemotherapy followed by autologous hematopoietic 
stem cell transplantation (ASCT). In CHOP group, 25 of 
82 patients received second-line chemotherapy, of which 
12 patients received rituximab-containing salvage regimens. 
In R-CHOP group, 23 of 95 patients received second-line 
treatment, of which 7 patients received rituximab-containing 
salvage chemotherapy. High-dose chemotherapy with ASCT 
was administered to 14 patients in CHOP group and 4 patients 
in R-CHOP group.
3. Survival outcomes 
A t  a  m e d i a n  f o l l o w - u p  d u r a t i o n  o f  5 2  m o n t h s  ( r a n g e ,  
34-92 months), the average 3-year EFS and OS rates in all 
177 patients were 62% and 74%, respectively. A comparison 
of survival outcomes according to treatment regimen re-
vealed 3-year EFS and OS rates of 52% and 69%, respectively, 
in the CHOP group at a median follow-up duration of 66 
months, and 3-year EFS and OS rates of 71% and 79%, 
respectively, in R-CHOP group at a median follow-up dura-
tion of 45 months. Overall, R-CHOP group displayed higher 
3-year EFS and OS rates, with a significant difference in 
EFS (P=0.01 using log-rank test). Kaplan-Meier curves for Korean J Hematol 2011;46:103-10.
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Fig. 1. Kaplan-Meier curves for (A) event-free survival and (B) overall survival in all 177 patients classified on the basis of the treatment regimen.
Fig. 2. Kaplan-Meier curves for (A) event-free survival and (B) overall survival in patients with nodal lymphoma; (C) event-free survival, and (D) 
overall survival in patients with primary extranodal lymphoma classified on the basis of the treatment regimen.
EFS and OS in the 2 groups are depicted in Fig. 1. Subgroup 
analyses for survival according to treatment regimen revealed 
that in terms of EFS, young age (≤60 years), female gender, 
good performance status (ECOG PS score of 0-1), advanced 
stages (stage III, V), lower number of extranodal sites (0 
or 1), absence of B symptoms, bone marrow involvement, Korean J Hematol 2011;46:103-10.
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Table 3. Prognostic factor analysis in the NL group (N=105).
Variable
Univariate analysis Multivariate analysis
EFS OS EFS OS
P
a) HR (95% CI) P
a) HR (95% CI) P
b) HR (95% CI) P
b) HR (95% CI)
Stage 
　I, II vs. III, IV 0.01 0.46 (0.25-0.87) 0.07 0.50 (0.24-1.07) 0.01 0.38 (0.19-0.72) 0.03 0.42 (0.19-0.93)
LDH
　Normal vs. elevated 0.02 0.44 (0.21-0.89) 0.09 0.49 (0.21-1.15) 0.16 0.60 (0.28-1.26) 0.43 0.70 (0.28-1.72)
Treatment regimen
　R-CHOP vs. CHOP 0.01 0.39 (0.21-0.72) 0.04 0.47 (0.23-0.99) 0.01 0.32 (0.17-0.62) 0.02 0.40 (0.18-0.87)
a)Log-rank test, 
b)Cox proportional hazard model.
Abbreviations: NL, nodal lymphoma; EFS, event-free survival; OS, overall survival; HR, hazard ratio; CI, Confidence interval; LDH, lactate 
dehydrogenase; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab-CHOP.
Table 4. Prognostic factor analysis in the PENL group (N=72).
Variable
Univariate analysis Multivariate analysis
EFS OS EFS OS
P
a) HR (95% CI) P
a) HR (95% CI) P
b) HR (95% CI) P
b) HR (95% CI)
ECOG PS 
　0-1 vs. ≥2 0.01 0.27 (0.11-0.68) 0.01 0.21 (0.08-0.54) 0.03 0.35 (0.13-0.91) 0.01 0.27 (0.10-0.74)
No. of extranodal sites
　0-1 vs. ＞1 0.10 0.49 (0.20-1.18) 0.03 0.37 (0.15-0.94) 0.60 0.76 (0.28-2.09) 0.49 0.68 (0.23-2.01)
LDH 
　Normal vs. elevated 0.02 0.34 (0.13-0.86) 0.02 0.29 (0.09-0.86) 0.07 0.41 (0.16-1.07) 0.10 0.37 (0.12-1.19)
Treatment regimen
　R-CHOP vs. CHOP 0.93 0.96 (0.43-2.17) 0.58 1.29 (0.52-3.18) −−− −
a)Log-rank test, 
b)Cox proportional hazard model.
Abbreviations: PENL, primary extranodal lymphoma; EFS, event-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; 
ECOG PS, Eastern Clinical Oncology Group performance scale; LDH, lactate dehydrogenase; CHOP, cyclophosphamide, doxorubicin, 
vincristine, and prednisone; R-CHOP, rituximab-CHOP.
lower IPI score (low or low-intermediate), and NL (versus 
PENL) were all factors associated with significant survival 
benefits following R-CHOP therapy, while in terms of OS, 
only NL patients (versus PENL) showed significant survival 
benefits from R-CHOP therapy compared to CHOP therapy. 
In particular, patients in NL group treated with R-CHOP 
therapy exhibited significantly higher survival rates than 
those administered the CHOP regimen (3-year EFS, 73% 
vs. 45%, P=0.002; 3-year OS, 83% vs. 65%, P=0.044; Fig. 
2A and 2B). In contrast, no survival benefit from R-CHOP 
therapy was evident in PENL patients (3-year EFS, 68% 
vs. 66%, P=0.93; 3-year OS, 73% vs. 74%, P=0.58; Fig. 2C 
and  2D). 
In addition, survival outcomes were compared between 
the PENL and the NL groups. No significant differences 
in t h e  3-year E F S (67%  v s.  59%) and OS (73% vs. 75%) 
rates were observed between the PENL and NL groups. 
Subgroup analysis was performed for each group. Univariate 
analysis in NL patients showed that the presence of earlier 
stages of the disease (stages I and II), normal lactate de-
hydrogenase (LDH) levels at diagnosis, and the use of the 
R-CHOP regimen were favorable prognostic factors for EFS, 
whereas R-CHOP therapy was the only favorable prognostic 
factor for OS. Multivariate analysis in the NL group further 
revealed that lower stage of the disease and R-CHOP therapy 
were independent prognostic factors for both EFS and OS 
(Table 3). On the other hand, in the PENL group, good 
performance status and normal LDH levels were favorable 
prognostic factors for EFS and OS in the univariate analysis, 
while good performance status was the only independent 
prognostic factor for both EFS and OS in the multivariate 
analysis (Table 4). These data clearly indicate that R-CHOP 
chemotherapy is not an effective prognostic factor to predict 
better survival of patients in the PENL group.
DISCUSSION
DLBCL is a heterogeneous disease entity in terms of clinical 
behavior, morphology, immunophenotype, and molecular 
characteristics. Several studies have attempted to identify 
differences in the clinical and molecular aspects of the Korean J Hematol 2011;46:103-10.
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Fig. 3. Kaplan-Meier curves for (A) event-free survival and (B) overall survival in patients treated with R-CHOP classified on the basis of the 
redistributed International Prognostic Index score.
disease. With the advent of rituximab, new challenges have 
arisen in relation to rituximab treatment of DLBCL patients. 
In this retrospective study, we established that the addition 
of rituximab to CHOP leads to better response and survival 
rates in patients with DLBCL, which is in accordance with 
earlier data [7-10]. Moreover, we identified an interesting 
prognostic factor for the efficacy of R-CHOP therapy. In 
our experiments, NL patients displayed significantly better 
response and survival rates upon treatment with the R-CHOP 
regimen than with CHOP therapy alone. Multivariate analy-
ses confirmed that R-CHOP therapy is an independent favor-
able prognostic factor for the survival of NL patients. On 
the other hand, PENL patients displayed no differences in 
response rates and survival duration upon treatment with 
the R-CHOP versus the CHOP regimens. In other words, 
patients with PENL did not benefit from the addition of 
rituximab to the CHOP regimen. Our findings suggest that 
the classification of DLBCL based on the major origin of 
the disease is important for predicting the response to ritux-
imab therapy. 
The superiority of the R-CHOP regimen to CHOP therapy 
has been confirmed in randomized prospective trials. In 2002, 
the Group d’Etudes des Lymphomes de l’Adulte (GELA) re-
ported survival benefits of R-CHOP over CHOP therapy 
in elderly patients with DLBCL. This group further updated 
these results at a median 5-year follow-up in 2005 [7, 8]. 
In the MabThera International Trial (MInT), Pfreundschuh 
et al. [10] reported that rituximab added to 6 cycles of CHOP 
therapy was an effective treatment for young patients with 
good-prognosis DLBCL. In addition, Sehn and colleagues 
[9] showed improved outcomes using a combination of CHOP 
therapy and rituximab in DLBCL patients of all ages in a 
population-based study. Clearly, R-CHOP is the best choice 
of treatment for patients with DLBCL at present. However, 
the factors affecting prognosis in patients treated with ritux-
imab remain to be established. The IPI or age-adjusted IPI 
score was reported as a useful factor to predict survival bene-
fits in patients treated with R-CHOP in earlier trials. In 
the GELA LNH98-5 study, OS was markedly but selectively 
improved in patients with low-risk age-adjusted IPI score 
(0-1), but not in those with high-risk age-adjusted IPI score 
(2-3) [8]. In contrast, Park et al. [26] reported survival benefits 
of R-CHOP in patients with high-risk IPI score (3-5). In 
our study, patients with low-risk IPI score (0-2) displayed 
significant improvement in EFS following R-CHOP therapy. 
Sehn and co-workers [12] suggested a revised IPI scale as 
a better predictor of outcomes for patients with DLBCL. 
In their study, no differences in survival were observed be-
tween low and low-intermediate groups or between high 
and high-intermediate groups. Accordingly, IPI scores were 
classified into 3 prognostic groups (0, 1-2, and 3-5). However, 
our findings showed no survival differences between low-in-
termediate and high-intermediate groups. In our study, the 
IPI scores were, therefore, classified into the following 3 
groups: 0-1, 2-3, and 4-5 risk factors (Fig. 3). 
In addition to the IPI score, our NL patients displayed 
significantly better EFS and OS outcomes with the R-CHOP 
regimen than did patients with PENL. Basic patient charac-
teristics between the NL and PENL subgroups were similar, 
except for the performance score. A higher number of pa-
tients in the NL subgroup had a good performance score 
(0-1) on th e ECOG scale. To  adjust  fo r t his diff erence bet ween 
the 2 subgroups, we excluded several patients with poor 
performance scores (2-4) from each subgroup. The results 
were not different. Patients in NL group treated with 
R-CHOP regimen showed better outcomes in terms of EFS 
and OS rates (P=0.006 and P=0.06, respectively) than those 
treated with CHOP. In contrast, no survival benefits with 
R-CHOP regimen were observed in PENL group (P=0.48 
and P=0.93, respectively). Multivariate analysis further con-
firmed that R-CHOP therapy is an independent prognostic 
factor for EFS and OS in NL group, but not in PENL group.Korean J Hematol 2011;46:103-10.
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Our data suggest that PENL is distinct from NL with regard 
to clinicopathologic behavior a n d  r e s p o n s e  t o  R - C H O P  
therapy. A number of studies suggested that the primary 
site of the lymphoma (either the lymph node or different 
extranodal territories) is a criterion that may be applied 
to separate the 2 different groups of DLBCL and attempted 
to identify differences in prognostic factors between PENL 
and NL for R-CHOP therapy. Kramer et al. [27] previously 
reported on the prognostic significance of Bcl-2 as a negative 
factor for disease-free survival with a high frequency in 
patients with NL. Mounier and colleagues [13] suggested 
a benefit of R-CHOP therapy in elderly Bcl-2-positive pa-
tients with DLBCL from the GELA LNH98-5 study. In their 
report, Bcl-2-positive patients treated with R-CHOP showed 
higher response rates and better 2-year OS than those treated 
with CHOP. In contrast, Bcl-2-negative patients displayed 
no significant differences in response rates and survival be-
tween the 2 treatment regimens. Patients with PENL pre-
sented more frequently with Bcl-6 expression than those 
with NL, as reported by Lopez-Guillermo and co-workers 
[28]. Winter et al. [14] reported that patients with Bcl-6-pos-
itive DLBCL did not benefit from the addition of rituximab 
to the CHOP regimen, while Bcl-6 protein expression was 
a powerful predictor of outcomes in DLBCL patients sub-
jected to CHOP chemotherapy. In this study, we did not 
investigate molecular markers, such as Bcl-2 and Bcl-6 and 
thus, could not determine whether there is a correlation 
between the expression of molecular markers and the out-
comes of the 2 treatment regimens in PENL and NL patients. 
Further studies are required to address this issue. 
The current study has several limitations, because it is 
a retrospective investigation based on cancer registry data 
with a relatively small sample size. Nevertheless, continuing 
efforts to identify patients who do not benefit from rituximab 
and identification of other treatment strategies for such pa-
tients, are essential in this rituximab era.
In conclusion, the rituximab plus CHOP regimen im-
proved outcomes in patients with newly diagnosed CD20- 
positive DLBCL compared with CHOP treatment alone. 
However, the addition of rituximab to CHOP chemotherapy 
was not beneficial for patients with PENL. Thus, other treat-
ment strategies need to be developed for this patient group.
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